# US 12,215,171 B2 · Rabbit antibodies to human immunoglobulins G

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,171 B2
- Document ID: US12215171B2
- Status: Granted
- Kind: B2
- Application number: 17/335,291
- Filed: 2021-06-01
- Published: 2021-12-09
- Granted: 2025-02-04
- Earliest claimed: 2020-06-01
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Ruiyin Chu
- Web page: https://patentgrep.com/patent/US12215171B2

## CPC

- C07K 16/18: against material from animals or humans
- C07K 16/4241: {against anti-human or anti-animal Ig}
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/6854: {Immunoglobulins}
- G01N 33/686: {Anti-idiotype}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure anti-human IgG antibodies and antigen-binding portions thereof derived from rabbits and methods of using these antibodies and portions.

## Claims

### Claim 1

An isolated monoclonal antibody or an antigen-binding portion thereof that binds specifically to human IgG, wherein the antibody or portion comprises heavy chain complementarity-determining region (CDR) 1-3 and light chain CDR1-3 respectively comprising
SEQ ID NOs: 27-32,
SEQ ID NOs: 33-38,
SEQ ID NOs: 39-44,
SEQ ID NOs: 45-50,
SEQ ID NOs: 51-56, or
SEQ ID NOs: 57-62.

### Claim 2 (depends on 1)

The monoclonal antibody or antigen-binding portion of claim 1, wherein the antibody or portion comprises heavy chain variable domain (VH) and light chain variable domain (VL) respectively comprising
SEQ ID NOs: 13 and 19,
SEQ ID NOs: 14 and 20,
SEQ ID NOs: 15 and 21,
SEQ ID NOs: 16 and 22,
SEQ ID NOs: 17 and 23, or
SEQ ID NOs: 18 and 24.

### Claim 3 (depends on 1)

The monoclonal antibody of claim 1, wherein the antibody is a rabbit IgG antibody.

### Claim 4 (depends on 1)

The monoclonal antibody of claim 1, comprising a heavy chain constant region amino acid sequence of SEQ ID NO: 25, and/or a light chain constant region amino sequence of SEQ ID NO: 26.

### Claim 5 (depends on 1)

The monoclonal antibody of claim 1, comprising a heavy chain and a light chain having the amino acid sequences of
SEQ ID NOs: 63 and 69,
SEQ ID NOs: 64 and 70,
SEQ ID NOs: 65 and 71,
SEQ ID NOs: 66 and 72,
SEQ ID NOs: 67 and 73, or
SEQ ID NOs: 68 and 74,
respectively, with or without the leader sequences.

### Claim 6 (depends on 1)

The monoclonal antibody or antigen-binding portion of claim 1, further comprising a detectable label.

### Claim 7 (depends on 1)

A composition or a kit comprising the monoclonal antibody or antigen-binding portion of claim 1 in an aqueous buffered solution.

### Claim 8 (depends on 1)

An isolated nucleic acid molecule encoding the heavy chain, the light chain, or both, of the monoclonal antibody or antigen-binding portion of claim 1.

### Claim 9 (depends on 8)

The nucleic acid molecule of claim 8, comprising SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and/or 12.

### Claim 10 (depends on 9)

The nucleic acid molecule of claim 9, comprising
SEQ ID NOs: 1 and 7,
SEQ ID NOs: 2 and 8,
SEQ ID NOs: 3 and 9,
SEQ ID NOs: 4 and 10,
SEQ ID NOs: 5 and 11, or
SEQ ID NOs: 6 and 12.

### Claim 11 (depends on 8)

An expression construct comprising the nucleic acid molecule of claim 8.

### Claim 12 (depends on 1)

A host cell comprising nucleotide sequences encoding the heavy chain and the light chain of the monoclonal antibody or antigen-binding portion of claim 1.

### Claim 13 (depends on 12)

The host cell of claim 12, wherein the host cell is a mammalian cell.

### Claim 14 (depends on 13)

A method of producing an antibody or an antigen-binding portion thereof, comprising:
culturing the host cell of claim 13 under conditions that allow expression of the heavy chain and light chain of the antibody or portion, and
isolating the antibody or portion from the cultured cell or the supernatant of the cell culture.

### Claim 15 (depends on 1)

A method of detecting human IgG or a fragment thereof in a sample, comprising contacting the sample with one or more monoclonal antibodies or antigen-binding portions of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sample is obtained from an animal that has been administered an antibody comprising a human IgG constant region or a fragment thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the human IgG constant region is a human IgG1, IgG2, IgG3, or IgG4 constant region.

### Claim 18 (depends on 15)

The method of claim 15, wherein the animal has been administered a Fab or F(ab′) 2 fragment of an antibody comprising a human IgG1, IgG2, IgG3, or IgG4 constant region.

### Claim 19 (depends on 15)

The method of claim 15, wherein the sample is a tissue sample.

### Claim 20 (depends on 15)

The method of claim 15, wherein the animal is a non-human primate.

### Claim 21 (depends on 19)

The method of claim 19, wherein the tissue sample is a blood, serum, or plasma sample.

### Claim 22 (depends on 20)

The method of claim 20, wherein the non-human primate is a cynomolgus monkey or rhesus monkey.